Search Results for "action"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for action. Results 471 to 480 of 1149 total matches.

Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000  (Issue 1081)
such as hyoscyamine (Levsin, and others), bulking agents such as psyllium, and antidepressants. MECHANISM OF ACTION ...
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.
Med Lett Drugs Ther. 2000 Jun 26;42(1081):53-4 |  Show IntroductionHide Introduction

Cevimeline (Evoxac) For Dry Mouth

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
, sugar-free gum, hard candy and saliva substitutes (Medical Letter, 30:74, 1988). MECHANISM OF ACTION ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Med Lett Drugs Ther. 2000 Aug 7;42(1084):70 |  Show IntroductionHide Introduction

Cool.click: A Needle-free Device For Growth Hormone Delivery

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
a release button. Spring action pushes the drug at high speed through a small opening in the nozzle ...
A new needle-free system (cool.click) has been approved by the FDA for subcutaneous delivery of Saizen (recombinant somatotropin - Serono). Somatotropin is used for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. Children with growth hormone deficiency require injections daily or several times weekly for many years.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):2-3 |  Show IntroductionHide Introduction

Anakinra (Kineret) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002  (Issue 1124)
anti-rheumatic drug (DMARD) such as methotrexate (Medical Letter 2000; 42:57). MECHANISM OF ACTION ...
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).
Med Lett Drugs Ther. 2002 Feb 18;44(1124):18-9 |  Show IntroductionHide Introduction

Low-Dose Doxepin (Silenor) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2010  (Issue 1348)
and in a liquid formulation. MECHANISM OF ACTION — The usual dosage of doxepin for treatment of depression ...
The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin (Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.
Med Lett Drugs Ther. 2010 Oct 4;52(1348):79-80 |  Show IntroductionHide Introduction

Lurasidone (Latuda) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011  (Issue 1358)
in humans) for use in pregnancy. Chemistry Benzoisothiazol derivative Mechanism of action Dopamine (D2 ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Med Lett Drugs Ther. 2011 Feb 21;53(1358):13-4 |  Show IntroductionHide Introduction

Potassium Iodide for Thyroid Protection in a Nuclear Accident

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011  (Issue 1361)
old have a much lower risk. MECHANISM OF ACTION — Potassium iodide is readily absorbed within 30-60 ...
Even though it is unlikely that people living in the US will be at risk of significant radiation exposure from the nuclear accident in Japan, some readers have suggested a review of the use of potassium iodide (KI) in such circumstances. Potassium iodide taken orally before or at the time of exposure can limit or prevent uptake of radioactive iodine by the thyroid gland.
Med Lett Drugs Ther. 2011 Apr 4;53(1361):25-6 |  Show IntroductionHide Introduction

Spinosad (Natroba) Topical Suspension for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011  (Issue 1367)
. It is available only by prescription. MECHANISM OF ACTION — Spinosad is a fermentation product of the soil ...
The FDA has approved spinosad 0.9% suspension (Natroba – ParaPro) for topical treatment of head lice infestation in patients ≥4 years old. It is available only by prescription.
Med Lett Drugs Ther. 2011 Jun 27;53(1367):50-1 |  Show IntroductionHide Introduction

Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2011  (Issue 1370)
MECHANISM OF ACTION — Abiraterone blocks biosynthesis of androgens by inhibiting CYP17, an enzyme required ...
The FDA has approved abiraterone acetate (Zytiga – Centocor Ortho Biotech) for oral treatment, in combination with prednisone, of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and others). It is the first oral drug approved for this indication. Zytiga will compete with cabazitaxel (Jevtana) and sipuleucel-T (Provenge).
Med Lett Drugs Ther. 2011 Aug 8;53(1370):63-4 |  Show IntroductionHide Introduction

Vemurafenib (Zelboraf) for Metastatic Melanoma

   
The Medical Letter on Drugs and Therapeutics • Oct 03, 2011  (Issue 1374)
from melanoma tissue. MECHANISM OF ACTION — BRAF V600E is a mutated kinase that results in activation of BRAF ...
The FDA has approved vemurafenib (Zelboraf – Genentech), a kinase inhibitor, for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation, which is found in 30-60% of melanomas. An FDA-approved test can detect the mutation in DNA from melanoma tissue.
Med Lett Drugs Ther. 2011 Oct 3;53(1374):77-8 |  Show IntroductionHide Introduction